How to optimize HCV therapy in genotype 4 patients. (Q38071388)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286845 AND SRC:MED&resulttype=core&format=json

21 February 2020

review article

1 reference

title

How to optimize HCV therapy in genotype 4 patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286845 AND SRC:MED&resulttype=core&format=json

21 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286845 AND SRC:MED&resulttype=core&format=json

21 February 2020

Mohamed El Kassas

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286845 AND SRC:MED&resulttype=core&format=json

21 February 2020

Mohamed Hassany

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286845 AND SRC:MED&resulttype=core&format=json

21 February 2020

Maissa El-Raziky

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286845 AND SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Mohamed Esmat Gamil

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286845 AND SRC:MED&resulttype=core&format=json

21 February 2020

publication date

1 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286845 AND SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286845 AND SRC:MED&resulttype=core&format=json

21 February 2020

volume

33 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286845 AND SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

41-45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286845 AND SRC:MED&resulttype=core&format=json

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

21 February 2020

cites work

1 reference

The future for the treatment of genotype 4 chronic hepatitis C.

21 January 2018

1 reference

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

21 January 2018

1 reference

Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.

21 January 2018

1 reference

High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy

21 January 2018

1 reference

Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy

21 January 2018

1 reference

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.

21 January 2018

1 reference

Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms

21 January 2018

1 reference

NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients

21 January 2018

1 reference

Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter?

21 January 2018

1 reference

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin

21 January 2018

1 reference

Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection.

21 January 2018

1 reference

Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4.

21 January 2018

1 reference

Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C.

21 January 2018

1 reference

Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss.

21 January 2018

1 reference

Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients

21 January 2018

1 reference

Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance

21 January 2018

1 reference

Differential effect of interferon on hepatitis C virus 1b quasispecies in the nonstructural protein 5A gene

21 January 2018

1 reference

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

21 January 2018

1 reference

Role of Helicobacter pylori in patients with HCV-related chronic hepatitis and cirrhosis with or without hepatocellular carcinoma: possible association with disease progression.

21 January 2018

1 reference

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

21 January 2018

1 reference

The way forward in HCV treatment--finding the right path

21 January 2018

1 reference

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

21 January 2018

1 reference

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study

21 January 2018

1 reference

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

American Gastroenterological Association technical review on the management of hepatitis C.

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

21 January 2018

1 reference

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin

21 January 2018

1 reference

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response

21 January 2018

1 reference

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response

21 January 2018

1 reference

Genomics and HCV infection: Progression of fibrosis and treatment response

21 January 2018

1 reference